Amarin reported $0 in Debt for its fiscal quarter ending in March of 2025.





Debt Change Date
AbbVie USD 1000K 70.48B Sep/2025
Alnylam Pharmaceuticals USD 1.3B 271.5M Jun/2025
Amarin USD 0 0 Mar/2025
AstraZeneca USD 32.84B 1.19B Jun/2025
DBV Technologies USD 8.59M 295K Sep/2025
GlaxoSmithKline GBP 17.75B 396M Sep/2025
Halozyme Therapeutics USD 1.51B 1.65M Jun/2025
Ionis Pharmaceuticals USD 1.23B 192.99M Sep/2025
Neurocrine Biosciences USD 439.1M 8.4M Jun/2025
Novartis USD 32.64B 1.37B Jun/2025